Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model

SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second out-licensing…

Beneath the biotech boom

It’s considered a scientific landmark: A 1975 meeting at the Asilomar Conference Center in Pacific Grove, California, shaped a new safety regime for recombinant DNA, ensuring that researchers would apply caution to gene splicing. Those ideas have been so useful that in the decades since, when new topics in scientific safety arise, there are still […] The post Beneath the biotech boom appeared first on OODAloop.

VelaVigo Announces Second Out-Licensing Deal, of a First-in-Class Bi-specific Antibody, Further Validating Its Innovative Discovery Platform and Sustainable BD+VC Business Model - PressReach

SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ — VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today announced its second out-licensing agreement of a first-in-class (FIC) asset to Ollin Biosciences, Inc. (“Ollin”), granting Ollin an exclusive license to develop, manufacture and commercia…

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

A hot antibody discovery team in China has signed its second US biotech deal in less than six months, marking the latest sign of the industry's flourishing wave of China-to-US drug development partnerships. The startup ...